Search Results - "Pi, Selina"

817: VONOPRAZAN IS ASSOCIATED WITH LOWER HEALTHCARE RESOURCE UTILIZATION AND COSTS THAN PPI-BASED THERAPY FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN JAPAN by Howden, Colin W., Cook, Erin, Pelletier, Corey, Jacob, Rinu, Yang, Karen, Pi, Selina, Sugano, Kentaro

Get full text

Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States by Ailawadhi, Sikander, Cheng, Mu, DerSarkissian, Maral, Dabora, Jonathan, Young, Melanie, Noga, Stephen J., Pi, Selina, Zhang, Melody, Banatwala, Azeem, Duh, Mei Sheng, Cherepanov, Dasha

Get full text

Tu1336: A REAL-WORLD STUDY OF PERSISTENCE AND ADHERENCE TO PRESCRIPTION MEDICATIONS IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION by Cash, Brooks D., Lu, Mei, Schoenfeld, Philip S., Feuerstadt, Paul, Nguyen, Linda Anh B., Terasawa, Emi, Ayyagari, Rajeev, Du, Shawn, Pi, Selina, Westermeyer, Ben, Terreri, Brian, Boules, Mena, Moshiree, Baha

Get full text

A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States by Cash, Brooks D, Lu, Mei, Lembo, Anthony, Feuerstadt, Paul, Nguyen, Linda, Terasawa, Emi, Ayyagari, Rajeev, Du, Shawn, Pi, Selina, Westermeyer, Ben, Terreri, Brian, Boules, Mena, Moshiree, Baharak

“…At present, 4 prescription therapies have been approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation (CIC) in…”
Get full text

Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor by Zakharia, Yousef, Huynh, Lynn, Du, Shawn, Chang, Rose, Pi, Selina, Sundaresan, Sanjana, Duh, Mei S., Zanotti, Giovanni, Thomaidou, Despina

“…There are limited real-world data on the effectiveness of strategies used to manage adverse events (AEs) in patients with advanced renal cell carcinoma (RCC)…”
Get full text

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States by Sanchez, Larysa, Chari, Ajai, Cheng, Mu, Cherepanov, Dasha, DerSarkissian, Maral, Huang, Fei, Stull, Dawn Marie, Dabora, Jonathan, Young, Melanie, Noga, Stephen J, Pi, Selina, Zhang, Melody, Banatwala, Azeem, Duh, Mei Sheng, Ailawadhi, Sikander

“…Economic differences among currently available proteasome inhibitors (PI)-based lenalidomide-dexamethasone (Rd)-backbone triplet regimens-ixazomib (I),…”
Get full text

Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States by Lembo, Anthony, Cash, Brooks D, Lu, Mei, Terasawa, Emi, Terreri, Brian, Du, Shawn, Ayyagari, Rajeev, Feuerstadt, Paul, Moshiree, Baharak, Westermeyer, Ben, Pi, Selina, Boules, Mena

“…This real-world US-based claims study compared constipation-related symptoms and complications 6 months before and after prucalopride initiation in adults with…”
Get full text

Using Case Mix Index within Diagnosis-Related Groups to Evaluate Variation in Hospitalization Costs at a Large Academic Medical Center by Pi, Selina, Masterson, Jonathan, Ma, Stephen P, Corbin, Conor K, Milstein, Arnold, Chen, Jonathan H

“…In analyzing direct hospitalization cost and clinical data from an academic medical center, commonly used metrics such as diagnosis-related group (DRG) weight…”
Get full text